Drug intelligence / Profile preview

Nutrika

Development stage: Unknown
Lead developer: AZKKA Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Nutrika is an oral nutritional supplement developed by AZKKA Pharmaceuticals, specifically formulated to address nutritional deficiencies and support patients with diabetic complications. It contains a combination of Methylcobalamin (1500 mcg), Alpha Lipoic Acid (200 mg), Biotin (200 mcg), Folic Acid (1.5 mg), Pyridoxine Hydrochloride (3 mg), and Vitamin D3 (1000 IU). This multivitamin and antioxidant blend is primarily indicated for diabetic neuropathy, nephropathy, and retinopathy. The formulation works by promoting nerve health and repair, improving metabolic processes, and providing essential vitamins for red blood cell production and antioxidant defense.

Brand names: Nutrika

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Nutrika.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutrika.

Explore the full profile